Combination phase II study of weekly paclitaxel and 5'-DFUR for unresectable or recurrent gastric cancer.

Shigefumi Yoshino, Takumi Furuya, Ryoichi Shimizu, Hiroaki Ozasa, Taku Nishimura, Shintaro Fukuda, Toru Kawaoka, Shoichi Hazama, Masaaki Oka

Index: Anticancer Res. 33(6) , 2629-33, (2013)

Full Text: HTML

Abstract

Paclitaxel and 5'-deoxy-5-fluorouridine (5'-DFUR) have single-agent activity in gastric cancer and have distinct mechanisms of action and no overlap of key toxicities. To evaluate the efficacy and safety of their combination, we conducted a combination phase II study of paclitaxel and 5'-DFUR in patients with unresectable or recurrent gastric cancer who had received up to one prior chemotherapy.Treatment included paclitaxel at 70 mg/m(2) i.v. on days 1, 8 and 15 every four weeks, and 5'-DFUR at 600 mg p.o. every day. The primary end-point was the response rate (RR) and secondary end-points were overall survival (OS), progression-free survival (PFS), time-to-treatment failure (TTF) and rate of adverse events.In 42 eligible patients, the RR was 40.5%. OS, PFS and TTF were 371 days, 170 days, and 147 days, respectively. Adverse events were relatively mild. Commonly observed grade 3/4 adverse events were neutropenia (26.2%), anorexia (4.8%), neuropathy (4.8%) and fatigue (4.8%).The combination of weekly paclitaxel and 5'-DFUR chemotherapy is active and well-tolerated.